MYNZ – mainz biomed n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
Mainz Biomed (NASDAQ: MYNZ) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
Mainz Biomed Reports Full Year 2023 Financial Results
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
Form D/A MAINZ BIOMED N.V.
Form 6-K MAINZ BIOMED N.V. For: Apr 24
Form 6-K MAINZ BIOMED N.V. For: Apr 18
Form 20-F MAINZ BIOMED N.V. For: Dec 31
Form 6-K MAINZ BIOMED N.V. For: Feb 23
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.